Short answer
Crinetics Pharmaceuticals, Inc. (CRNX) filed an 8-K current report with the SEC on August 14, 2026 reporting Item 8.01 (Other Events). HSR antitrust waiting period expired August 12, 2026, removing the primary U.S. regulatory hurdle.
Crinetics Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- HSR antitrust waiting period expired August 12, 2026, removing the primary U.S. regulatory hurdle
- Austria, Germany, and Australia approvals received, with Australia waiting period scheduled to expire August 27, 2026
- Vertex acquisition still requires Crinetics shareholder approval at the August 28, 2026 special meeting
- Closing expected in early September 2026, subject to remaining conditions and no termination events
- Transaction outcome remains exposed to closing delays, litigation, competing offers, and integration risks
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Crinetics Pharmaceuticals, Inc. 8-K filings
Get the next CRNX 8-K as it lands
Follow CRNX for push alerts, or ask the research agent what this filing means.